Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2020

The Pharma Closeout tracks 62 deals, $183.3B in disclosed deal value, 32 with a post-close Outcome Score for the year 2020.

Median Critic Score: 80  ·  Median Outcome Score: 51

Best outcome: Pfizer Inc. / BioNTech SE (100)  ·  Weakest outcome: Gilead Sciences Inc. / Forty Seven Inc. (18)

All 62 deals

• Pfizer Inc. / BioNTech SE — 2020 · $748M · Worked — the deal delivered on its rationale.
• Servier SA / Agios Pharmaceuticals (oncology) — 2020 · $2.0B · Worked — the deal delivered on its rationale.
• Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. — 2020 · $2.0B · Worked — the deal delivered on its rationale.
• Novo Nordisk A/S / Emisphere Technologies — 2020 · $1.4B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Alexion Pharmaceuticals Inc. — 2020 · $39.0B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amgen Inc. — 2020 · $2.3B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Genmab A/S — 2020 · $3.9B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / MyoKardia Inc. — 2020 · $13.1B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Momenta Pharmaceuticals Inc. — 2020 · $6.5B · Largely worked — most objectives met.
• Amgen Inc. / BeiGene Ltd. — 2020 · $2.8B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Immunomedics Inc. — 2020 · $21.0B · Largely worked — most objectives met.
• AstraZeneca PLC / Daiichi Sankyo Company, Limited — 2020 · $6.0B · Largely worked — most objectives met.
• Merck & Co. Inc. / VelosBio Inc. — 2020 · $2.8B · Largely worked — most objectives met.
• Illumina, Inc. / Amgen Inc. — 2020 · Mixed — partial payoff, real shortfalls.
• Bristol-Myers Squibb Company / Dragonfly Therapeutics Inc. — 2020 · $475M · Mixed — partial payoff, real shortfalls.
• Pfizer Inc. / CStone Pharmaceuticals — 2020 · $780M · Mixed — partial payoff, real shortfalls.
• GlaxoSmithKline plc / Vir Biotechnology Inc. — 2020 · $595M · Mixed — partial payoff, real shortfalls.
• Bayer AG / Asklepios BioPharmaceuticals — 2020 · $2.0B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Prevail Therapeutics — 2020 · $1.0B · Mixed — partial payoff, real shortfalls.
• Bayer AG / Viralgen — 2020 · Mixed — partial payoff, real shortfalls.
• Novavax Inc. / Praha Vaccines — 2020 · $167M · Mixed — partial payoff, real shortfalls.
• Novartis AG / Molecular Partners AG — 2020 · $780M · Mixed — partial payoff, real shortfalls.
• Gilead Sciences Inc. / Arcus Biosciences, Inc. — 2020 · $5.0B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Kiadis Pharma NV — 2020 · $359M · Underwhelmed — fell short of the thesis.
• Sanofi SA / Principia Biopharma — 2020 · $3.7B · Underwhelmed — fell short of the thesis.
• Illumina, Inc. / GRAIL, Inc. — 2020 · $8.0B · Underwhelmed — fell short of the thesis.
• Metuchen Pharmaceuticals / Neurotrope Inc — 2020 · $20M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / Blueprint Medicines Corporation — 2020 · $1.7B · Underwhelmed — fell short of the thesis.
• Merck & Co. Inc. / Seagen Inc. — 2020 · $4.2B · Did not work — the deal failed to deliver.
• Boehringer Ingelheim GmbH / NBE Therapeutics — 2020 · $1.5B · Did not work — the deal failed to deliver.
• AbbVie Inc. / I-Mab — 2020 · $2.9B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Forty Seven Inc. — 2020 · $4.9B · Did not work — the deal failed to deliver.
• Hypera S.A. / Takeda Pharmaceutical Company Limited — 2020 · $825M
• AstraZeneca PLC / Allergan plc — 2020 · $250M
• Roche Holding AG / Atea Pharmaceuticals, Inc. — 2020 · $1.4B
• Sanofi SA / Kymera Therapeutics, Inc. — 2020 · $2.1B
• Pfizer Inc. / Vivet Therapeutics S.A.S. — 2020
• Bayer AG / Asklepios BioPharmaceutical, Inc. (AskBio) — 2020 · $4.0B
• Eli Lilly and Company / Dermira Inc. — 2020 · $1.1B
• Nestle S.A. / Aimmune Therapeutics, Inc. — 2020 · $2.6B
• Swedish Orphan Biovitrum AB (Sobi) / Apellis Pharmaceuticals, Inc. — 2020 · $1.0B
• Bristol-Myers Squibb Company / Repare Therapeutics Inc. — 2020 · $3.1B
• Servier SA / Symphogen A/S — 2020
• Johnson & Johnson / Fate Therapeutics, Inc. — 2020 · $3.1B
• Pfizer Inc. / Valneva SE — 2020 · $308M
• Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. — 2020 · $1.4B
• GlaxoSmithKline plc / CureVac N.V. — 2020 · $960M
• Merck & Co. Inc. / Taiho Pharmaceutical / Astex Pharmaceuticals — 2020 · $2.5B
• Cerevel Therapeutics / ARYA Sciences Acquisition Corp II — 2020 · $445M
• Sanofi SA / Translate Bio Inc. — 2020 · $2.3B
• Bayer AG / Recursion Pharmaceuticals, Inc. — 2020 · $1.1B
• Pfizer Inc. / Myovant Sciences Ltd. — 2020 · $4.2B
• Biogen Inc. / Sangamo Therapeutics, Inc. — 2020 · $2.7B
• Blackstone Group Inc. / Alnylam Pharmaceuticals Inc. — 2020 · $2.0B
• PTC Therapeutics Inc. / Censa Pharmaceuticals — 2020 · $268M
• Boehringer Ingelheim GmbH / NBE-Therapeutics AG — 2020 · $1.4B
• Eli Lilly and Company / Shanghai Junshi Biosciences Co., Ltd. — 2020 · $255M
• Roche Holding AG / Regeneron Pharmaceuticals, Inc. — 2020
• Moderna, Inc. / Lonza Group AG — 2020
• Roche Holding AG / Bicycle Therapeutics plc — 2020 · $1.7B
• Nestle S.A. / Allergan plc — 2020
• Ionis Pharmaceuticals, Inc. / Akcea Therapeutics, Inc. — 2020 · $500M

← Deal Library  ·  Interactive search  ·  How we score deals